Ramucirumab | 雷莫芦单抗

MCE 国际站：Ramucirumab

中文名：雷莫芦单抗

CAS：947687-13-0

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Ramucirumab 是一种人类 VEGFR-2 拮抗剂，用于治疗实体瘤。 Ramucirumab 是一种重组人免疫球蛋白 G1 单克隆抗体，可结合 VEGFR-2 的细胞外结合域并阻止 VEGFR 配体：VEGF-A、VEGF-C 和 VEGF-D 的结合。 Ramucirumab 还是一种血管生成抑制剂^[1][2]。 IC50 和靶标：VEGFR^[2] 

体外：Ramucirumab (10 μg/mL) 阻碍 VEGF 和肿瘤驱动的索形成^[3]。Ramucirumab 不与小鼠 VEGFR2 发生交叉反应^[3] .

热销产品：Bimekizumab  | WM-8014  | 5'-Methylthioadenosine  | Teriparatide  | Prexasertib  | p-SCN-Bn-DOTA  | Palivizumab  | Nicotinamide riboside (chloride)  | CCR2 antagonist 1  | PDK4-IN-1 (hydrochloride)

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：VEGFR

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

参考文献：[1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53.[2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5.[3]. Lowery CD, et al. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget. 2019 Sep 17;10(53):5523-5533.